Cargando…
Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease
Hyperphosphatemia is a risk factor for ectopic calcification and coronary artery diseases in end stage renal diseases (ESRD). The aim of this study was to assess the effect of low-dose nicotinic acid on hyperphosphatemia in patients with ESRD. This randomized, double-blind clinical trial was done on...
Autores principales: | Zahed, N. S., Zamanifar, N., Nikbakht, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964682/ https://www.ncbi.nlm.nih.gov/pubmed/27512294 http://dx.doi.org/10.4103/0971-4065.161020 |
Ejemplares similares
-
Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective
por: Reddy, Yogesh NV, et al.
Publicado: (2014) -
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009) -
Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia
por: Cui, Xiaofei, et al.
Publicado: (2022) -
Hyperphosphatemia and risks of acute kidney injury, end-stage renal disease, and mortality in hospitalized patients
por: Moon, Hongran, et al.
Publicado: (2019) -
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020)